Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Impact of initial FLT3-ITD mutated clone numbers on clinical outcomes in Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

SPSilvia ParkCMChang‐Ki Min

Discussion

Loading...

Member takes

Overview

Analysis reveals increased therapeutic resistance and poorer survival linked to multiple FLT3-ITD clones in AML patients, highlighting prognostic significance.

Key Points

  • Multiclone FLT3-ITD status significantly shortens overall survival in patients with acute myeloid leukemia, pointing to treatment implications.
  • Survival rate is 1.6 years for multiclone versus 1.8 years for monoclone patients, suggesting increased risk.
  • Retrospective analysis used multivariable analysis to identify predictors of survival outcomes based on FLT3-ITD clone status.
  • Results indicate the need for molecular testing of FLT3-ITD clones for risk stratification in AML treatment.

Cite This Study

Park et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e470https://doi.org/10.1182/blood-2025-1638
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Diagnostic evaluation methods and prognostic impact of FLT3-ITD microclones in Acute Myeloid Leukemia (AML): A retrospective multicenter study on behalf of the EHA AML-specialized working group (SWG)2025 · 1 citations
  2. 2Clonal dynamics of FLT3-ITD positive acute myeloid leukemia following relapse after allogeneic stem cell transplantation2025
  3. 3Prognostic impact of co-occurring FLT3 mutations across molecular subgroups in intensively treated acute myeloid leukemia: Insights from real-world genomic data2025
  4. 4Clonal timing of FLT3-ITD dictates evolutionary trajectory and phenotypic heterogeneity in acute myeloid leukemia2025
  5. 5DNMT3A, NPM1, and FLT3-ITD triple-mutated AML has a favorable prognosis in the era of FLT3 inhibitors2025 · 2 citations